GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaLundensis AB (XSAT:PHAL) » Definitions » ROC (Joel Greenblatt) %

PharmaLundensis AB (XSAT:PHAL) ROC (Joel Greenblatt) % : -978.58% (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is PharmaLundensis AB ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. PharmaLundensis AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -978.58%.

The historical rank and industry rank for PharmaLundensis AB's ROC (Joel Greenblatt) % or its related term are showing as below:

XSAT:PHAL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7572.37   Med: -884.76   Max: -234.9
Current: -1070.57

During the past 13 years, PharmaLundensis AB's highest ROC (Joel Greenblatt) % was -234.90%. The lowest was -7572.37%. And the median was -884.76%.

XSAT:PHAL's ROC (Joel Greenblatt) % is ranked worse than
68.23% of 1454 companies
in the Biotechnology industry
Industry Median: -333.28 vs XSAT:PHAL: -1070.57

PharmaLundensis AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


PharmaLundensis AB ROC (Joel Greenblatt) % Historical Data

The historical data trend for PharmaLundensis AB's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaLundensis AB ROC (Joel Greenblatt) % Chart

PharmaLundensis AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,234.59 -1,157.89 - - -850.55

PharmaLundensis AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,786.84 -1,102.84 -775.98 -1,187.67 -978.58

Competitive Comparison of PharmaLundensis AB's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, PharmaLundensis AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaLundensis AB's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaLundensis AB's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where PharmaLundensis AB's ROC (Joel Greenblatt) % falls into.



PharmaLundensis AB ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (1.588 + 0 + 1.065)
=-2.653

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (1.461 + 0 + 1.156)
=-2.617

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of PharmaLundensis AB for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4.34/( ( (0.457 + max(-2.653, 0)) + (0.43 + max(-2.617, 0)) )/ 2 )
=-4.34/( ( 0.457 + 0.43 )/ 2 )
=-4.34/0.4435
=-978.58 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaLundensis AB  (XSAT:PHAL) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


PharmaLundensis AB ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of PharmaLundensis AB's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaLundensis AB (XSAT:PHAL) Business Description

Traded in Other Exchanges
N/A
Address
Medicon Village, Scheelevagen 2, Lund, SWE, 22381
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.

PharmaLundensis AB (XSAT:PHAL) Headlines

No Headlines